Literature DB >> 16720464

The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease.

Michael Beck1.   

Abstract

UNLABELLED: Fabry disease is a rare lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A. The resultant storage of undegraded glycolipids leads to the progressive development of potentially life-threatening manifestations affecting multiple organ systems in the body. This paper describes the development of the Mainz Severity Score Index (MSSI), a scoring system for patients with Fabry disease.
CONCLUSION: The MSSI score has been proven to be representative in patients with 'classic' Fabry disease and may be useful for monitoring clinical improvement in patients receiving enzyme replacement therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16720464     DOI: 10.1080/08035320600618825

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  15 in total

1.  Carpal tunnel syndrome in fabry disease.

Authors:  Joanna Ghali; Anand Murugasu; Timothy Day; Kathy Nicholls
Journal:  JIMD Rep       Date:  2011-09-06

2.  A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.

Authors:  Trevor F Cox; Lakshminarayan Ranganath
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

3.  Natural history of alkaptonuria revisited: analyses based on scoring systems.

Authors:  Lakshminarayan R Ranganath; Trevor F Cox
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 4.  The Psychosocial Impact of Carrying a Debated Variant in the GLA Gene.

Authors:  Sarah Macklin; Dawn Laney; Emily Lisi; Andrea Atherton; Elizabeth Smith
Journal:  J Genet Couns       Date:  2017-08-10       Impact factor: 2.537

5.  Social-adaptive and psychological functioning of patients affected by Fabry disease.

Authors:  Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta
Journal:  J Inherit Metab Dis       Date:  2010-01-20       Impact factor: 4.982

6.  Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Wouter Wieling; Frits A Wijburg; Carla E M Hollak
Journal:  BMC Neurol       Date:  2010-06-07       Impact factor: 2.474

7.  Leukocyte perturbation associated with Fabry disease.

Authors:  P Rozenfeld; E Agriello; N De Francesco; P Martinez; C Fossati
Journal:  J Inherit Metab Dis       Date:  2009-03-07       Impact factor: 4.982

8.  Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Authors:  Bouwien E Smid; Saskia M Rombach; Johannes M F G Aerts; Symen Kuiper; Mina Mirzaian; Hermen S Overkleeft; Ben J H M Poorthuis; Carla E M Hollak; Johanna E M Groener; Gabor E Linthorst
Journal:  Orphanet J Rare Dis       Date:  2011-10-31       Impact factor: 4.123

9.  Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease.

Authors:  Gulfidan Bitirgen; Kultigin Turkmen; Rayaz A Malik; Ahmet Ozkagnici; Nazmi Zengin
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

10.  Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease.

Authors:  Diana Hernández-Romero; Jessica Sánchez-Quiñones; Juan Antonio Vílchez; José Miguel Rivera-Caravaca; Gonzalo de la Morena; Gregory Y H Lip; Vicente Climent; Francisco Marín
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.